Evaluation of EGFR amplification and TERTp mutation in a background of wild-type IDH1/2 in lower-grade gliomas could help to identify aggressive tumors with seemingly low grade histology, facilitating a more precise prognostic estimation. This evidence concerns the gene IDH1 and glioma.